血清CA125动态变化与上皮性卵巢癌患者预后关系的初探

Relationship between the kinetics of serum CA125 and the prognosis of epithelial ovarian carcinoma patients

目的 探讨血清CA12 5动态变化与卵巢癌患者预后的关系。方法 应用放免法测定手术前后以及应用含铂类的联合化疗过程中血清CA12 5水平 ,并回顾分析CA12 5的动态变化、转阴时间和半衰期与患者预后的关系。结果 所有上皮性卵巢癌患者术前CA12 5均大于正常值 ,且晚期肿瘤明显高于早期肿瘤 ;CA12 5转阴时间 (NT)与肿瘤期别有一定关系 ,NT≤ 8周者平均 4年生存率高于NT >8周者 ;T1 2 ≤ 2 0d者平均存活 3 6个月 ,而 >2 0d者 ( 3 0例 )平均存活 2 5个月。结论 血清CA12 5转阴时间和半衰期对上皮性卵巢癌患者的预后有较重要的提示价值。重视治疗后 8周或第 3次化疗前血清CA12 5水平 ,对于适时调整临床治疗方案有重要的指导作用。

Objective To investigate the relationship between the dynamic changes of serum CA125 and the prognosis of epithelial ovarian carcinoma (EOC) patients. Methods The CA125 serum levels were determined by radioimmunoassay before and after operation and during platinum-based combination chemotherapy in 48 EOC patients. The kinetics, half-life time (T 1/2 ), the time for normalization (NT) of CA125, and the prognosis of EOC patients were analyzed retrospectively. Results The pre-operative CA125 level higher than 35 U/ml was found in each EOC patient. The average four-year-survival rate of patients with CA125 level below the upper normal limit at 8 weeks after operation was higher than that of patients without normal CA125 (P<0.05). There was a close correlation between the half-life and the survival rate. The average survival time of patients with T 1/2 <20 d and T 1/2 > d was 36 and 25 months, respectively. Conclusion CA125 is well established as an accurate and reliable means for monitoring the response to treatment of EOC. It is possible to predict treatment response by the half-time of CA125 during chemotherapy and the time needed for normalization of CA125 levels can be used to divide patients into good and poor prognostic groups early during chemotherapy.